PERNETTA –A non comparative randomized open label phase II trial of pertuzumab(P) + trastuzumab(T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2 positive metastatic breast cancer (SAKK 22/10 / UNICANCER UC-0140/1207). 

J. Huober, P. Weder, C. Veyret, B. Thürlimann, et al. 

POSTER

 

Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks.

A. Müller, A.J. Templeton, S. Hayoz, H. Hawle, et al.

POSTER

 

TAILORED AXILLARY SURGERY WITH OR WITHOUT AXILLARY LYMPH NODE DISSECTION FOLLOWED BY RADIOTHERAPY IN PATIENTS WITH CLINICALLY NODE-POSITIVE BREAST CANCER (TAXIS): A MULTICENTER RANDOMIZED PHASE-III TRIAL.  

Henke G, Knauer M, Ribi K, Hayoz S, et al. 

POSTER